Dr Julie Douville is the Senior Director of Preclinical Development at n-Lorem. Prior to n-Lorem, Julie was at Charles River Laboratories from 2007 to 2022 as the Director of Infusion, Parenteral Administration and Neurotoxicology, where she specialized in cerebrospinal administration, and in the development of antisense oligonucleotides, gene therapies and other therapeutic entities. In this role, Julie oversaw several IND-supporting programs for indications including ALS, Alzheimer’s Disease, Parkinson’s, Angelman’s Syndrome, Duchenne’s Muscular Dystrophy, and many others. Working with academic investigators, she personally oversaw the toxicology program for milasen, the first personalized ASO treatment that was customized for a mutation in a single patient, which was approved for clinical use by the FDA in 2018. Julie led several additional n=1 preclinical programs, in addition to being involved on many other rare disease programs for which she developed strategies for acceleration of the preclinical phase. She has taken part in key discussions with regulatory authorities in the FDA and EMA, helping to establish precedents for the U.S. guidelines around individualized antisense oligonucleotide treatment. Julie brings to n-Lorem a strong background in GLP preclinical development, and indepth knowledge of ASO-associated toxicities, especially in the central nervous system. Julie received her PhD in Microbiology and Immunology from the University of Montreal.